Currently, that limit is a blood alcohol concentration (BAC) of .08%, but many people still dont know how much alcohol .08 is
Safety and Tolerability Key Findings: AOD-9604 has been shown to be safe and well-tolerated in clinical trials, with no reported impact on IGF-1 levels or growth hormone pathways
Unlike some peptides where more is simply better, IGF-1 LR3 has a relatively narrow therapeutic window
The room temperature stability data makes this impact very clear
The initial inflammatory modulation begins within the first one to two weeks, but the functional changes, including improved flexibility, reduced global stiffness, and better circulation, accumulate over four to eight weeks as the compounds systemic effects build through repeated dosing